May 2026 · 9 min read · Clinical Protocol
What Counts as "Severe" Low Back Pain?
Severe low back pain (sLBP) is defined clinically as VAS ≥ 7/10 or NRS ≥ 7/10 with significant functional impairment (ODI > 40%), lasting over 6 weeks or recurring frequently. This category includes: chronic low back pain, acute exacerbations of herniated discs, lumbar spinal stenosis, facet joint syndrome, and lumbar radiculopathy. These patients have typically already tried NSAIDs, physiotherapy, and injections — and are still in pain.
How PEMF Works on Severe Back Pain
Four parallel mechanisms explain PEMF's effect on deep spinal structures:
- Membrane depolarization of nociceptive neurons — raises the firing threshold of A-δ and C fibers, reducing spinal synaptic pain transmission.
- Activation of adenosine-A2A receptors in the spinal dorsal horn, suppressing glutamate and substance P release.
- Improved perivertebral microcirculation and reduced interstitial edema around compressed nerve roots.
- Reduced pro-inflammatory cytokines (IL-1β, TNF-α) in disc and epidural space.
The 2025 Multicenter RCT
A multicenter randomized controlled trial (PMC11914662, n=91 completers, 5 orthopedic clinics) demonstrated:
- 36% pain reduction in the PEMF group vs. 10% in standard care (p<0.0001)
- 55% reduction in medication consumption vs. 12% in control group
- In crossover subgroups, patients switched from standard care to PEMF experienced an additional 18% pain improvement and 63% medication reduction
This is the most rigorous PEMF dataset published to date for low back pain.
Clinical Protocol
- Patient positioning: sitting or lying down
- Coil placement: lumbar, sacro-iliac, or thoraco-lumbar region based on pathology
- Treatment frequency: 1–2 times per week; up to 3 times weekly in severe cases (rest day between sessions)
- Session duration: 30–40 minutes
- Series length: minimum 3 sessions; continuation determined by VAS/ODI improvement
- Expected timeline: initial improvement sometimes after 2–3 sessions; full measured improvement after 6–12 weeks of consistent twice-weekly treatment
PEMF vs. Conventional Treatments
| Parameter | PEMF | NSAIDs/Opioids | Physiotherapy Alone | Surgery |
|---|---|---|---|---|
| Pain reduction (2025 RCT) | 36% | Variable | 10% | Variable |
| Medication reduction | 55% | N/A | 12% | Depends |
| Non-invasive | Yes | Yes (oral) | Yes | Highly invasive |
| FDA cleared | Yes (510k) | Yes | N/A | N/A |
| Adverse effects | Very rare | GI, kidney, addiction risk | Minimal | Surgical risk |
| Monitoring required | No | No | No | Yes (hospital) |
Integrating PEMF with Other Modalities
Most effective clinical combination: PEMF + osteopathic manual therapy + functional exercise.
- PEMF: reduces deep tissue inflammation and nociception — preparing the tissue for structural work
- Manual therapy: releases structural blockages — more effective after PEMF has reduced inflammation
- Exercise: consolidates gains and prevents recurrence
This three-channel approach is used in the majority of Israel's 60+ PainFree clinics.
Who Can Receive Treatment?
Broad eligibility: chronic pain patients, athletes, elderly, children, post-surgical patients, patients with complex neurological/orthopedic backgrounds. Contraindications are narrow: active pacemaker, pregnancy, active epilepsy, active malignancy in treatment area.
What This Means for Clinic Investors
Severe low back pain patients are the highest-value segment for PEMF clinics: they've failed other treatments, they're motivated, and they complete full treatment courses (10–20 sessions). The 36% pain reduction figure isn't just clinically meaningful — it's the marketing story that fills appointment books.
Request the full investor package.
Request Investment Brief →